ARCHIVES

FDA Approves NDA For Mylan’s Paclitaxel For Ovarian And Breast Cancer Treatment.

This article is from The Cancer Letter archive.

Vol. 27 No. 30 | July 27, 2001

Download PDF Visit The Full Archive

Related Articles

NCI Moves Ahead To Find “Less-Hazardous” Cigarette

April 19, 1974

Community Assn. Meeting Includes Provocative Workshops

January 31, 1975

Clinical Oncology Programs Extended Two Years; No Decision Yet On Further Expansion

November 3, 1978

Flood Mistrial

February 9, 1979

FDA, NCI Seek Compromise On Survival Endpoints

June 16, 1989

Only 10% Of Breast Cancer Patients May Benefit From Contralateral Mastectomy

March 26, 2010